Chelation in Metal-Induced Diseases
A special issue of Toxics (ISSN 2305-6304). This special issue belongs to the section "Human Toxicology and Epidemiology".
Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 2666
Special Issue Editor
2. Ex-Director, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research-Raebareli, Transit Campus, Lucknow, India
Interests: chemical toxicity; toxicity of metals; arsenic poisoning; drug development; organ toxicity; mechanism of toxicity; oxidative medicine; chelation therapy
Special Issue Information
Dear Colleagues,
Occupational and environmental risks for human health derived from metal exposure are of concern. Hereditary conditions such as Wilson’s disease caused by excess copper accumulation, or patients with secondary iron overload (thalassemia major), require treatment because of the excess accumulation of these metals. The reduction of aluminum accumulation and toxicity following chelation may also prove beneficial in end-stage renal disease patients, and perhaps those suffering from neurodegenerative disorders such as Alzheimer's disease (AD). Chelation therapy has been practiced in various forms for more than five decades. The development of organic compounds capable of reducing body toxic burden continues to be an area of general importance. Metal complexes formed with these metal ions and chelating agents in vivo are readily excreted in the urine or feces, leading to the reduction of toxic metal burden. Neurodegenerative disorders are a group of heterogeneous diseases characterized by protein deposition within neurons or brain parenchyma and oxidative stress. Although most neurodegenerative, hepatic, renal, cardiovascular, and bone disorders have distinct and characteristic etiologies, they share striking similarity with respect to metal discrepancies. Recognizing the metal-based hypothesis of diseases, chelation therapy has been proposed to break bonds between metals and proteins/enzymes etc. and reduce organ toxicity along with the possible restoration of metal homeostasis.
We welcome manuscripts focused on the effect of chelation in various metal/metalloid-induced diseases. Manuscripts should fall within one or more of the following topics of interest:
Synthesis and characterization of new chelating agents; isolation and characterization of phytochemicals against metal-induced neurological disorders; effectiveness of conventional chelators against metal-induced neurodegenerative/hepatic/renal/cardiovascular diseases; chelation therapy against cardiovascular diseases like Wilson’s disease, Alzheimer’s, and Parkinsonism; effectiveness against carcinogenesis etc.; clinical studies describing the efficacy of chelation in the recovery of numerous metal-induced human diseases; recent discoveries about natural-based molecules with potential organ protective activity; alternative strategies such as pharmaceutical engineering approaches explored for enhancing the efficacy of natural-based molecules; preclinical and clinical studies of phyto-pharmaceuticals; toxicity assessment of these synthetic and natural-based products; as well as regulatory challenges or considerations for natural-based products.
The present Special Issue thus welcomes high-quality manuscripts/review papers on the above theme. There is still a substantial lack of relevant and reliable data as well as definitive conclusions regarding the clinical advantages of chelation in neurodegenerative conditions. Such papers will be given priority.
Dr. Swaran J. S. Flora
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurodegerative diseases
- cardiovascular diseases
- organ toxicity
- toxic metals/metalloids
- phytochemicals
- chelation therapy
- clinical trials
- synthesis of new chelating agents
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
